A pilot randomized, controlled trial of the effect of iron depletion on long-term response to α-interferon in patients with chronic hepatitis C

Journal of Hepatology

Volumn 28, Issue 3, 1998, Pages 369-374

  Fong, Tse Ling ^a   Han, Steven H ^a   Tsai, Naoky C S ^b   Morgan, Timothy R ^c   Mizokami, Masashi ^d   Qianp, Dajun ^a   Phan, Charles ^c   Goad, Kimberly ^b   Redeker, Allan G ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b St Francis Healthcare System of Hawaii   (United States)

^c VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^d NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

Aminotransferase; Phlebotomy

Indexed keywords

ALANINE AMINOTRANSFERASE; FOLIC ACID; IRON; RECOMBINANT ALPHA2B INTERFERON; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HEPATITIS C; HUMAN; IRON DEFICIENCY; LIVER CELL CARCINOMA; LIVER CIRCULATION; LIVER FAILURE; MALE; PHLEBOTOMY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0032032484     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(98)80308-5     Document Type: Article

References (35)

1. Davis GL, Balart LA, Schiff ER, Lindsay KL, Bodenheimer HC, Perillo RP. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial. N Engl J Med. 321:1989;1501-1505.
2. DiBisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, et al. Recombinant interferon alfa therapy for chronic hepatitis C: a randomized, double-blind placebo-controlled trial. N Engl J Med. 321:1989;1506-1510.
3. Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, et al. Comparison of 1 or 3 mu of interferon alfa 2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology. 101:1991;497-502.
4. Fried MW. Therapy of chronic viral hepatitis. Med Clin North Am. 80:1996;957-972.
5. Olynyk JK, Reddy KR, Di Bisceglie AM, Jeffers LJ, Parker TI, Radick JL, et al. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology. 108:1995;1104-1109.
6. Van Thiel DH, Friedlander L, Fargiuoli S, Wright HI, Irish W, Gavaler JS. Response to interferon α therapy is influenced by the iron content of the liver. J Hepatol. 20:1994;410-415.
7. Arber N, Moshkowitz M, Konikoff F, Halpern Z, Hallak A, Santo M, et al. Elevated serum iron predicts poor response to interferon treatment in patients with chronic HCV infection. Dig Dis Sci. 40:1995;2431-2433.
8. Girelli CM, Mirata C, Lesinigo E, Casiraghi A. Iron overload and response to α-interferon in chronic hepatitis C. Am J Gastroenterol. 90:1995;170-171.
9. Barton AL, Banner BF, Cable EE, Bonkovsky HL. Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy. Am J Clin Pathol. 103:1995;419-424.
10. Hayashi H, Takikawa T, Nishimura N, Yano M, Isomura T, Sakamoto N. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic hepatitis active hepatitis C and excess hepatic iron. Am J Gastroenterol. 89:1994;986-988.
11. Hayashi H, Takikawa T, Nishimura N, Yano M. Serum aminotransferase levels as an indicator of the effectiveness of venesection for chronic hepatitis C. J Hepatol. 22:1995;268-271.
12. Davis GL, Lau JY-K, Urdea MS, Neuwald PD, Wilber JC, Lindsay KL, et al. Quantitative detection of hepatitis C viral RNA with a solid phase signal amplification method: definition of optimal conditions for specimen collection and clinical amplification in interferon-treated patients. Hepatology. 19:1994;1337-1341.
13. Cristiano K, Di Bisceglie AM, Hoofnagle JH, Feinstone SM. Hepatitis C viral RNA in serum of patients with chronic non-A, non-B hepatitis. Detection by the polymerase chain reaction using multiple primer sets. Hepatology. 14:1991;51-55.
14. Ohno T, Mitzokami M, Wu R-R, Saleh MG, Ohba K-I., Orito E, Mukaide M, et al. A new hepatitis C genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a and 6a. J Clin Microbiol. 35:1997;201-207.
15. Morgan EH. Iron metabolism and transport. Zakim D, Boyer TD. Hepatology. A Textbook of Liver Disease. 1996;526-553 Saunders, Philadelphia.
16. Firinati F, Cardin R, De Maria N, Libera GD, Marafin C, Lecis E, et al. Iron storage, lipid peroxiadation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol. 22:1995;449-456.
17. Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology. 25:1997;759-768.
18. Fargion S, Piperno A, Cappellini MD, Sampietro M, Fracanzani AL, Romano R, et al. Hepatitis C virus and porphyria cutanea tarda: evidence of a strong association. Hepatology. 16:1992;1322-1326.
19. Herrero C, Vicente A, Bruguera M, Ercilla MG, Barrera JM, Vidal J, et al. Is hepatitis C virus infection a trigger of porphyria cutanesa tarda? Lancet. 341:1993;788-789.
20. Murphy A, Dooley S, Hillary IB, Murphy GM. HCV infection in porphyria cutanea tarda. Lancet. 341:1993;1534-1535.
21. Lacour JP, Bodokh I, Castanet J, Bekri S, Ortonne JP. Porphyria cutanea tarda and antibodies to hepatitis C virus. Br J Dermatol. 128:1993;121-123.
22. DeCastro M, Sanchez J, Herrera JF, Chaves A, Duran R, Garcia-Buey L, et al. Hepatitis C virus antibodies and liver disease in patients with porphyria and cutanea tarda. Hepatology. 17:1993;551-557.
23. Piperno A, Fargion S, D'Alba R, Roffi L, Fracanzani AL, Vecchi L, et al. Liver damage in Italian patients with hereditary hemochromatosis is highly influenced by hepatitis B and C virus infection. J Hepatol. 16:1992;364-368.
24. Brudieux E, de Ledinghen V, Oui B, Trimoulet P, Raymond JM, de Verneuil H, et al. Porphyrin metabolism disorders in patients with hepatitis C virus infection [abstract]. Hepatology. 24:1996;150.
25. Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. Measurements of iron status in patients with chronic hepatitis. Gastroenterology. 102:1992;2108-2113.
26. Kugelmas M, Yen Leiberman B, Carey WD. Deironization in chronic hepatitis C patients previously non-responsive to interferon improves transaminases but not viral activity[abstract]. Gastroenterlogy. 108:1995;1104.
27. Bacon BR, Rebholz AE, Fried MW, Di Bisceglie AM. Beneficial effect on iron reduction therapy in patients with chronic hepatitis C who failed to respond to interferon α [abstract]. Hepatology. 18:1993;150.
28. Herrera JL. Effects of phlebotomy in patients with chronic hepatitis C who failed to respond to a prior course of interferon α-2b [abstract]. Hepatology. 24:1996;404.
29. Guyader D, Boucher E, Even C, Cottereau J, Bianchi A, Gasser P, et al. Iron reduction therapy is inefficient in patients with chronic hepatitis C who failed to respond to interferon [abstract]. Hepatology. 24:1996;405.
30. Baeuerle PA. Inducible transcription activator NF-κB: Regulation by distinct protein subunits. Biochem Biophys Acta. 1072:1991;63-80.
31. Fong T-L, Valinluck B, Govindarajan S, Charboneau F, Adkins RH, Redeker AG. Effects of prednisone therapy on aminotransferase acitivity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology. 107:1994;196-199.
32. Takano S, Ito Y, Yokosuka O, Ohto M, Uchiumi K, Hiro K, et al. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology. 20:1994;558-564.
33. Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurhaydin C, et al. Ribavirin as therapy for chronic hepatitis C: a randomized, double-blinded, placebo-controlled trial. Ann Intern Med. 123:1995;897-903.
34. Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol. 25:1996;591-598.
35. Tsai NC-S, Zuckerman E, Han S-H, Goad K, Redeker AG, Fong T-L. The effect of iron depletion on long-term response to α interferon in patients with chronic hepatitis C who previously did not respond to interferon therapy. Am J Gastroenterol. 92:1997;1831-1834.